Morning Trend | CHINARES PHARMA consolidates with reduced volume, is a breakout imminent?

Technical Forecast
2025.12.09 01:00
portai
I'm PortAI, I can summarize articles.

Yesterday, China Resources Pharmaceutical (3320.HK) maintained a low-volume oscillating trend, with the stock price gradually dipping towards the 30-day moving average. Pharmaceutical stocks have recently been in a weak range, with overall capital showing an outflow pattern, and defensive allocation preferences dominating. As the national medical insurance negotiation phase approaches, there is a lack of significant positive news, and some major players are choosing to remain inactive or reduce holdings in advance, leading to a spread of wait-and-see sentiment. From a technical perspective, the MACD daily structure has shown a clear death cross, with short-term momentum leaning bearish. The 5-day and 10-day moving averages are stuck in a stalemate, indicating weak bullish momentum and a slight advantage for the bears. Throughout the day, net capital flow slightly outflowed, further indicating that major players have no intention of deep involvement in the short term. Considering the strong sensitivity of the pharmaceutical sector to news, future events such as medical insurance price adjustments and generic drug bidding may become important catalysts for short-term breakthroughs, which need to be closely monitored. Currently, China Resources Pharmaceutical maintains a box oscillation pattern. If there are clear policy developments or if the pharmaceutical sector shows new incremental movements, it could become a point for right-side capital to test new actions. However, the operational nodes remain unclear, and the sector carries significant risks; any blind chasing of price increases can easily increase risk exposure. There are high requirements for position management, and close attention should be paid to intraday trading and position changes, adjusting response strategies in conjunction with policy signals. In summary, although China Resources Pharmaceutical is under short-term pressure, the adjustment range is gradually approaching a relatively supportive area